• Female subjects aged ≥ 18 years.

• Histologically confirmed breast or gynecologic cancer.

• Developed neuropathic pain with the initiation of or within one month after completion of treatment with anti-neoplastic agents from the following class:

‣ Platinum-based drugs

⁃ Taxanes

⁃ Vinca alkaloids

• Pain score 4 or more on the Pain Numeric Rating Scale (PNRS).

• Score 3 or more on the Douleur Neuropathique 4 (DN-4) questionnaire.

• Persistent neuropathic pain with current use of at least one neuropathic medication.

• Subjects must have been on a stable dose of neuropathic pain medication for at least 6 weeks prior to enrollment.

• \-- Note: Additional washout periods for other pain medications may be needed and will be determined by the Investigator.

• For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply:

‣ Women \< 50 years of age:

• Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and

∙ Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or

∙ Underwent surgical sterilization (bilateral oophorectomy or hysterectomy).

⁃ Women ≥ 50 years of age:

• Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or

∙ Had radiation-induced menopause with last menses \>1 year ago; or

∙ Had chemotherapy-induced menopause with last menses \>1 year ago; or

∙ Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy).

• Subjects of childbearing potential must agree to use a highly effective method of contraception as described in Section 5.4.1.

• Able to provide informed consent and willing to sign an approved consent form that conforms to federal and institutional guidelines.